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Clostridium difficile is a significant nosocomial and community-acquired pathogen, and is 
the leading cause of antibiotic-induced diarrhea associated with high morbidity and mor-
tality. Given that the treatment outcome depends on the severity of C. difficile infection 
(CDI), we aimed to establish an efficient method of assessing severity, and focused on the 
stool biomarker fecal calprotectin (FC). FC directly reflects the intestinal inflammation sta-
tus of a patient, and can aid in interpreting the current guidelines, which requires the inte-
gration of indirect laboratory parameters. The distinction of 80 patients with CDI versus 71 
healthy controls and 30 severe infection cases versus 50 mild cases was possible using 
FC as a marker. The area under the receiver operating characteristic curves were 0.821 
and 0.746 with a sensitivity of 75% and 70% and specificity of 79% and 80%, for severe 
versus mild cases, respectively. We suggest FC as a predictive marker for assessing CDI 
severity, which is expected to improve the clinical management of CDI.
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INTRODUCTION
Clostridium difficile is a significant nosocomial and community-
acquired pathogen, and is the leading cause of antibiotic-induc ed 
diarrhea [1, 2]. C. difficile infection (CDI) diagnosis currently re-
lies on clinical manifestations of diarrhea, fever, abdominal pain, 
and leukocytosis, supported by laboratory confirmation of toxi-
genic C. difficile in the stool or colonoscopic ﬁndings consistent 
with pseudomembranous colitis (PMC). CDI is associated with 
high morbidity and mortality, thus, to improve CDI management 
and clinical outcome, several guidelines have been suggested 
as factors to help define severe CDI, including patients’ age, 
body temperature, serum albumin level, and peripheral white 
blood cell count [3-6]. However, the proposed severity assess-
ments have limitations, and not all recommended laboratory 
findings are readily accessible, making comprehensive integra-
tion difficult. Moreover, monitoring CDI after initiating therapy is 
often necessary, especially when a patient is treated with vanco-
mycin. However, concerns exist regarding the risk of prolonged 
vancomycin use, which would exert selection pressure to pro-
mote the colonization and transmission of vancomycin-resistant 
enterococci and increase systemic side effects in patients with 
renal failure [7].
Recently, non-invasive fecal biomarkers that reflect intestinal 
inflammation were identified, and their CDI diagnostic values 
were evaluated [8]. Fecal lactoferrin, a fecal material derived 
from neutrophils, has been shown to correlate with CDI severity 
[9]. In addition, mRNA of C-X-C motif chemokine 5 (CXCL-5) 
and mRNA and protein of interleukin (IL)-8 correlated with clini-
cal outcome [10], whereas positive guaiac-based fecal occult 
blood (FOB) showed low sensitivity in diagnosing CDI [11]. How-
ever, except for FOB, the previously investigated biomarkers are 
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not currently available for in vitro diagnostic use in Korea, and 
only fecal calprotectin (FC) level is currently used for examining 
intestinal inflammation [12]. 
FC, a 36.5-kDa molecule derived from the cytoplasm of neu-
trophils, mononuclear cells, and squamous epithelial cells, indi-
cates the inflammatory status of the intestinal lumen [13]. The 
role of FC was examined in many other gastrointestinal diseases 
such as inflammatory bowel disease (IBD), acute gastroenteritis, 
and malignancies [14]. The use of FC in CDI diagnosis was also 
demonstrated in a few studies; however, this marker showed re-
stricted utility for assessing CDI severity [11, 15]. We investigated 
demographics of subjects according to severity of CDI and dem-
onstrated the diagnostic value of FC to determine its potential as 
an alternative biomarker for monitoring CDI severity. 
METHODS
1. Subjects 
Seventy-one healthy control subjects and 80 CDI subjects were 
randomly selected for this retrospective study. Subjects were re-
cruited among patients whose stool samples were requested for 
routine fecal immunochemical test in medical examinations and 
for C. difficile culture, respectively, between March and October 
of 2015. This study was conducted at a University tertiary refer-
ral hospital in Seoul, South Korea, and it was approved by the 
Intstitutional Review Board of Severance Hospital. The demo-
graphics of subjects were assessed by reviewing hospital records 
and laboratory results (Table 1). 
2. Definitions 
Since FC level can be increased under some circumstances [16], 
subjects without possible intestinal inflammation were selected 
as healthy controls. CDI patients were strictly defined by the pres-
ence of symptoms, usually including diarrhea, and a positive 
test for toxigenic C. difficile culture as determined by GeneXpert 
C. difficile PCR assay (Cepheid, Sunnyvale, CA, USA) and toxin 
B PCR. 
CDI patients were divided into mild and severe groups based 
on a severity assessment score developed by Zar et al [6]. Pa-
tients with a score of ≥2 were considered to have severe CDI. 
One point each was given for age of >60 yr, body temperature 
>38.3°C, albumin level <25 g/L, or peripheral white blood cell 
count >15×109 cells/L within 48 hr of enrollment. In the case 
of endoscopic evidence of PMC or treatment in the intensive care 
Table 1. Baseline characteristics of patients with Clostridium difficile infection according to disease severity
Characteristics 
N (%) of patients
P value
Mild disease (n =  50) Severe disease (n =  30)
Male 21 (42) 11 (37) 0.637
Age, median (yr) 59 (range, 49-73) 71 (range, 60-79) 0.025
>60 yr of age 23 (46) 22 (73) 0.017
Received antibiotic therapy prior to onset of CDI 44 (88) 26 (86) 1.000
Received antibiotic therapy within 14 days prior to onset of CDI 41 (82) 24 (80) 0.824
Underlying diseases
Cardiovascular disease and/or hypertension 27 (54) 17 (57) 0.816
Malignancy 17 (34) 12 (40) 0.589
Chronic respiratory disease 6 (12) 6 (20) 0.351
Diabetes mellitus 9 (18) 8 (27) 0.359
Renal failure 12 (24) 12 (40) 0.131
Factors associated with disease severity
Hospitalized in the ICU 1 (2) 4 (13) 0.063
Body temperature >38.3°C 3 (8) 8 (30) 0.042
Serum albumin level <25 g/L 1 (2) 8 (27) 0.002
WBC count >15×109 cells/L 1 (2) 8 (27) 0.002
Presence of pseudomembranous colitis 2 (5) 4 (13) 0.394
Fecal calprotectin (μg/g) 188.2 (41.4-591.6) 1,391.5 (range, 173.5-2,075.9)
Abbreviations: CDI, Clostridium difficile infection; WBC, white blood cell count; ICU, intensive care unit. 
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Fig. 1. ROC curve analysis of fecal calprotectin concentrations in Clostridium difficile infection (CDI) cases and healthy controls. (A) The 
area under the ROC curve (AUC) is 0.746 (95% confidence interval [CI], 0.626-0.866) in severe CDI vs mild CDI; (B) The AUC is 0.821 
(95% CI, 0.755-0.887) in CDI vs healthy controls. 
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unit, 2 points were given. 
3. Measurement of FC 
FC was measured in a single frozen stool sample from all sub-
jects by using a commercially available ELISA kit: Calprotectin 
Bühlmann ELISA (Bühlmann Laboratories AG, Schönenbuch, 
Switzerland). Experimental samples were assayed with the stan-
dards and controls included with the kit according to the manu-
facturer’s instructions. The supernatants were diluted 3-fold if a 
higher concentration was expected. 
4. Statistical analyses 
Statistical analyses were performed by using SPSS software (ver-
sion 23.0; SPSS Inc., Chicago, IL, USA). Means of normally dis-
tributed quantitative values in more than two groups were com-
pared by one-way analysis of variance, whereas non-normally 
distributed quantitative values were compared by using the Krus-
kal-Wallis test. Non-parametric tests were used to determine 
whether clinical characteristics differed between the mild CDI 
group and severe CDI group, including the Mann-Whitney U 
test, Pearson’s chi-square test, and Fisher’s exact test. A two-
tailed value of P <0.05 was considered statistically signiﬁcant. 
ROC curve was analyzed to identify the optimal cut-off values 
for our study. 
RESULTS
1. Characteristics of CDI patients
Among the 80 CDI subjects enrolled in the study, 50 had mild 
CDI and 30 had severe CDI. Baseline characteristics are shown 
in Table 1. There was no statistically significant difference in the 
history of antibiotic therapy between the two groups or in spe-
cific underlying diseases.
2.  Diagnostic accuracy of FC and cut-off values according to 
CDI severity 
The median FC level was significantly higher (1,391.5 μg/g; in-
terquartile range [IQR]=173.5-2,075.9 μg/g) in the severe CDI 
group than in the mild CDI group (188.2 μg/g; IQR=41.4-591.6 
μg/g) (P <0.001). The area under the ROC curve (AUC) was 
0.746 for CDI severity with an optimum FC value of 729.8 μg/g, 
sensitivity of 70%, and specificity of 80% between severe CDI 
and mild CDI cases. The AUC was 0.821 for CDI diagnosis, with 
an optimum FC value of 112.5 μg/g, sensitivity of 75%, and spec-
ificity of 79% between CDI and non-CDI cases (Fig. 1).
FC concentrations were higher (P <0.001) in the 30 severe 
CDI patients (median, 1,391.5 μg/g; IQR, 170.0-2,088.1 μg/g) 
than in the 50 mild CDI patients (median, 188.2 μg/g; IQR, 41.4-
188.2 μg/g), and both were higher than those of the healthy 
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controls (median, 35.6 μg/g; IQR, 10.7-108.9 μg/g) (P =0.019 
and P <0.001 for mild CDI and severe CDI, respectively) (Fig. 2).
DISCUSSION 
Careful consideration is essential when changing antibiotic regi-
mens, and prompt and objective evidence can guide appropri-
ate therapy [17]. However, many approaches currently used in 
the laboratory diagnosis of CDI are time-consuming and costly, 
providing limited information on disease severity [18]. Accord-
ing to the current guidelines, when initiating antibiotic therapy is 
necessary, oral metronidazole is recommended in cases of non-
severe CDI and vancomycin is recommended for severe or re-
fractory CDI [4]. Therefore, it is important to confirm infection 
severity with a reliable biomarker, which can in turn serve as a 
guide for selecting antibiotic regimens that best reflect CDI sta-
tus. This objective assessment would allow for improved patient 
care to overcome the current limitations of continuous monitor-
ing and to reduce side effects and the potential for therapeutic 
resistance.
The diagnostic significance of FC has been assessed in many 
gastrointestinal disorders, and its concentration in healthy sub-
jects is generally below 50 μg/g [19], which was concordant 
with the levels of the subjects included in our study. However, 
FC concentrations have been reported to be as high from 994 
mg/L [11] to about 2,000 μg/g [15]. Eleven CDI patients (13.8% 
of the 80 patients) in this study had high FC concentrations (over 
2,000 μg/g), including one patient with a level of 6,000 μg/g who 
had a total severity score of 3 points, with persistent watery diar-
rhea and fulminant PMC. These findings indicate greater intesti-
nal inflammation, which may reflect the significant morbidity and 
mortality associated with severe CDI.
Previous studies have shown the diagnostic utility of FC in CDI, 
in which the patients’ status was confirmed by a combination of 
toxin ELISA, quantitativePCR, or toxigenic C. difficile culture, 
which differs from the more accurate practice of CDI diagnosis 
routinely performed in our hospital, where the diagnosis is made 
by toxigenic C. difficile culture, GeneXpert C. difficile PCR assay, 
and toxin B PCR [15, 20]. Furthermore, to verify the diagnostic 
significance of FC, we strictly excluded patients and healthy con-
trols with gastrointestinal disorders other than CDI, which can 
influence FC levels.
Here, we demonstrated that FC significantly correlated with 
CDI severity and could effectively discriminate among severe 
CDI, mild CDI, and healthy controls. FC showed a particularly 
strong ability to distinguish CDI patients from healthy controls 
according to the respectable AUC value, higher sensitivity, and 
high specificity.
There are currently no guidelines concerning the use of fecal 
biomarkers for estimating CDI severity. Fecal biomarkers have 
been proposed and widely studied as potential non-invasive al-
ternatives in IBD research; however, potential biomarkers that 
can serve as indicators of disease and disease stratification are 
also needed to more effectively direct CDI treatment. We sug-
gest FC as a predictive marker for assessing CDI severity, which 
is expected to improve the clinical management of this condition.
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